Regeneron previously announced initial results from the Phase 3 trial, which was jointly run with the COVID-19 Prevention Trials Network (CoVPN) National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Thus, we believe there is a significant need for complementary medicines such as REGEN-COV to help prevent the spread of SARS-CoV-2 infection, particularly in these immunocompromised patients." In addition, growing evidence suggests that a substantial number of individuals, such as the immunocompromised, will not respond satisfactorily to vaccines. "Despite the increased uptake of vaccines, SARS-CoV-2 has not been eradicated. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer at Regeneron. "This peer-reviewed NEJM publication demonstrates that REGEN-COV provides rapid and robust protection to prevent SARS-CoV-2 infection, and follows data showing that REGEN-COV maintains effectiveness against all variants of concern," said George D.
#New england journal of medicine articles trial#
The trial met its primary endpoint, reducing the risk of symptomatic infections by 81% (p<0.001), with a 93% reduction of symptomatic infections after the first week, and no dose-limiting toxicities observed. 4, 2021 /PRNewswire/ - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine (NEJM) published positive detailed results from a Phase 3 trial that assessed the ability of REGEN-COV (casirivimab and imdevimab) to prevent COVID-19 infection among household contacts of SARS-CoV-2 infected individuals. New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection
0 kommentar(er)
